CSF1R and neoplasm: In mouse models of solid tumors including colon cancer, breast cancer, and glioblastoma, monoclonal antibodies or small molecule inhibitors against CSF1R reduces the number of TAM and/or changes the phenotype of TAM, which impairs tumor development and progression (DeNardo et al., 2011; Pyonteck et al., 2013; Ries et al., 2014).